Serum level of interleukin-33 and soluble ST2 and their association with disease activity in patients with behcet's disease

Journal of Korean Medical Science

Volumn 28, Issue 8, 2013, Pages 1145-1153

  Kim, Dae Jun ^a   Baek, Seung Ye ^a   Park, Mi Kyung ^a   Park, Kyung Su ^a   Lee, Jae Ho ^a   Park, Sung Hwan ^a   Kim, Ho Youn ^a   Kwok, Seung Ki ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Behcet syndrome; Interleukin 33; Soluble ST2

Indexed keywords

C REACTIVE PROTEIN; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ARTICLE; BEHCET DISEASE; BLOOD; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-33; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SKIN; SOLUBLE ST2;

BEHCET SYNDROME; INTERLEUKIN-33; SOLUBLE ST2;

ADULT; BEHCET SYNDROME; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKINS; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 84884357817     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2013.28.8.1145     Document Type: Article

References (24)

1. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-90.
2. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One 2008; 3: e3331.
3. Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J 1994; 13: 1176-88.
4. Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 1999; 38: 728-33.
5. Shahram F, Khabbazi A, Nadji A, Ziaie N, Banihashemi AT, Davatchi F. Comparison of existing disease activity indices in the follow-up of patients with Behçet's disease. Mod Rheumatol 2009; 19: 536-41.
6. Verri WA Jr, Souto FO, Vieira SM, Almeida SC, Fukada SY, Xu D, Alves-Filho JC, Cunha TM, Guerrero AT, Mattos-Guimaraes RB, et al. IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann Rheum Dis 2010; 69: 1697-703.
7. Han GW, Zeng LW, Liang CX, Cheng BL, Yu BS, Li HM, Zeng FF, Liu SY. Serum levels of IL-33 is increased in patients with ankylosing spondylitis. Clin Rheumatol 2011; 30: 1583-8.
8. Mok MY, Huang FP, Ip WK, Lo Y, Wong FY, Chan EY, Lam KF, Xu D. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2010; 49: 520-7.
9. Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun 2001; 284: 1104-8.
10. Yang Z, Liang Y, Xi W, Li C, Zhong R. Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clin Exp Med 2011; 11: 75-80.
11. Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S. IL-33 and IL-33 receptors in host defense and diseases. Allergol Int 2010; 59: 143-60.
12. Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, Ishii A, Nambu A, Abe T, Kiyonari H, Matsumoto K, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A 2010; 107: 18581-6.
13. Hong YS, Moon SJ, Joo YB, Jeon CH, Cho ML, Ju JH, Oh HJ, Heo YJ, Park SH, Kim HY, et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci 2011; 26: 1132-9.
14. Kageyama Y, Torikai E, Tsujimura K, Kobayashi M. Involvement of IL-33 in the pathogenesis of rheumatoid arthritis: the effect of etanercept on the serum levels of IL-33. Mod Rheumatol 2012; 22: 89-93.
15. Mu R, Huang HQ, Li YH, Li C, Ye H, Li ZG. Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. J Rheumatol 2010; 37: 2006-13.
16. Kunisch E, Chakilam S, Gandesiri M, Kinne RW. IL-33 regulates TNF-α dependent effects in synovial fibroblasts. Int J Mol Med 2012; 29: 530-40.
17. Chen T, Jia RZ, Guo ZP, Cao N, Li MM, Jiao XY. Elevated serum interleukin-33 levels in patients with Henoch-Schönlein purpura. Arch Dermatol Res 2013; 305: 173-7.
18. Ciccia F, Alessandro R, Rizzo A, Raimondo S, Giardina A, Raiata F, Boiardi L, Cavazza A, Guggino G, De Leo G, et al. IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis. Ann Rheum Dis 2013; 72: 258-64.
19. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G, Girard JP. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A 2007; 104: 282-7.
20. Sayinalp N, Ozcebe OI, Ozdemir O, Haznedaroǧlu IC, Dündar S, Kirazli S. Cytokines in Behçet's disease. J Rheumatol 1996; 23: 321-2.
21. Mildner M, Storka A, Lichtenauer M, Mlitz V, Ghannadan M, Hoetzenecker K, Nickl S, Dome B, Tschachler E, Ankersmit HJ. Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc Res 2010; 87: 769-77.
22. Oshikawa K, Yanagisawa K, Tominaga Si, Sugiyama Y. ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation. Biochem Biophys Res Commun 2002; 299: 18-24.
23. Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004; 173: 145-50.
24. Yin H, Huang BJ, Yang H, Huang YF, Xiong P, Zheng F, Chen XP, Chen YF, Gong FL. Pretreatment with soluble ST2 reduces warm hepatic ischemia/ reperfusion injury. Biochem Biophys Res Commun 2006; 351: 940-6.